Finnish Mobidiag secures EUR 25 million from EIB to accelerate the development and commercialisation of in vitro diagnostic solutions for infectious diseases. This is the second operation between the EIB and Mobidiag after first loan in 2016.
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of infectious diseases and antimicrobial resistance, has signed a EUR 25 million growth capital loan with the European Investment Bank (EIB). The EIB loan will be supported by the European Fund for Strategic Investments (EFSI), the main pillar of the Investment Plan for Europe, through the European Growth Finance Facility (EGFF) initiative. This new four-year loan will allow Mobidiag to advance its research and development and facilitate further validation and commercialisation of molecular diagnostics tests on the Company’s Amplidiag® and Novodiag® platforms.
Tuomas Tenkanen, CEO of Mobidiag, said: “This EIB loan is a further validation of Mobidiag’s progress as we become a leading player in the molecular diagnostics market providing innovative and differentiated solutions that are adopted by key laboratories throughout Europe. Following extensive R&D and clinical validation, we are proud that our state-of-the-art technology is now commercially available internationally. This loan will allow us to accelerate the development of the Mobidiag platform content to the next level, and build significant value over the coming years by building a comprehensive portfolio of diagnostics tests that can be used on our devices. We are delighted to have the EIB’s support and look forward to working with them again.”
At the signature, EIB Vice-President Alexander Stubb, remarked: “Boosting the innovation capacity of a European life science business and helping to preserve relevant sectoral know-how in Europe is of major importance right now. The EIB used to be known as an infrastructure bank, but in recent years it has made an important shift towards supporting innovative companies, and very noticeably so in Finland. Our support has helped Mobidiag to continue its growth, and we’re glad to renew our commitment to this great company.”
